STOCK TITAN

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

Ladenburg Thalmann is hosting a Scientific Showcase webinar on December 18, 2024, focusing on Jaguar Health's (NASDAQ:JAGX) clinical development of crofelemer, their plant-based anti-diarrheal drug. The event will highlight five ongoing clinical efforts for rare disease indications: three proof-of-concept investigator-initiated trials and two Phase 2 studies targeting microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) across US, EU, and Middle East/North Africa regions. Initial proof-of-concept results are expected in Q2 2025. The company also announced that Massimo Radaelli, CEO of Napo Therapeutics and President of Jaguar International, was named 'Best Pharmaceuticals Innovator of the Year - Europe' by The European publication.

Ladenburg Thalmann ospiterà un webinar Scientific Showcase il 18 dicembre 2024, incentrato sullo sviluppo clinico di Jaguar Health (NASDAQ:JAGX) per il crofelemere, il loro farmaco antidiarroico di origine vegetale. L'evento metterà in evidenza cinque progetti clinici in corso per indicazioni di malattie rare: tre studi proof-of-concept avviati da ricercatori e due studi di Fase 2 mirati alla malattia da inclusione a microvilli (MVID) e alla sindrome dell'intestino corto con insufficienza intestinale (SBS-IF) nelle regioni degli Stati Uniti, dell'UE e del Medio Oriente/Nord Africa. I risultati preliminari proof-of-concept sono attesi nel secondo trimestre del 2025. La compagnia ha anche annunciato che Massimo Radaelli, CEO di Napo Therapeutics e Presidente di Jaguar International, è stato nominato 'Miglior Innovatore Farmaceutico dell'Anno - Europa' dalla pubblicazione The European.

Ladenburg Thalmann llevará a cabo un seminario web Scientific Showcase el 18 de diciembre de 2024, centrado en el desarrollo clínico del Jaguar Health (NASDAQ:JAGX) de crofelemere, su medicamento antidiarreico a base de plantas. El evento destacará cinco esfuerzos clínicos en curso para indicaciones de enfermedades raras: tres ensayos iniciados por investigadores como prueba de concepto y dos estudios de Fase 2 que apuntan a la enfermedad de inclusión por microvellos (MVID) y síndrome de intestino corto con fallo intestinal (SBS-IF) en las regiones de EE. UU., UE y Medio Oriente/Norte de África. Se esperan resultados preliminares de prueba de concepto en el segundo trimestre de 2025. La compañía también anunció que Massimo Radaelli, CEO de Napo Therapeutics y Presidente de Jaguar International, fue nombrado 'Mejor Innovador Farmacéutico del Año - Europa' por la publicación The European.

라덴부르크 탈만은 2024년 12월 18일에 재규어 헬스(NASDAQ:JAGX)의 식물 기반 항설사제인 크로펠레메르에 대한 임상 개발을 중심으로 한 '과학 쇼케이스' 웨비나를 개최합니다. 이 행사는 희귀 질병 적응증에 대한 진행 중인 5개의 임상 연구를 강조할 것입니다: 연구자 주도 3개의 개념 증명 시험과 미국, 유럽, 중동/북아프리카 지역에서 장 실조가 있는 미세융모 포함 질환(MVID) 및 단장 증후군(SBS-IF)을 겨냥한 2개의 2상 연구입니다. 초기 개념 증명 결과는 2025년 2분기에 예상됩니다. 또한 회사는 나포 테라퓨틱스의 CEO이자 재규어 인터내셔널의 회장인 마시모 라다엘리가 유럽의 '올해의 최고의 제약 혁신가'로 선정되었다고 발표했습니다.

Ladenburg Thalmann organisera un webinaire Scientific Showcase le 18 décembre 2024, axé sur le développement clinique du Jaguar Health (NASDAQ:JAGX) pour le crofelemere, leur médicament antidiarrhéique à base de plantes. L'événement mettra en lumière cinq efforts cliniques en cours concernant des indications de maladies rares : trois essais initiés par des chercheurs en tant que preuve de concept et deux études de Phase 2 ciblant la maladie d'inclusion à microvillos (MVID) et le syndrome de l'intestin court avec insuffisance intestinale (SBS-IF) dans les régions des États-Unis, de l'UE et du Moyen-Orient/Afrique du Nord. Les résultats initiaux de preuve de concept sont attendus au deuxième trimestre 2025. L'entreprise a également annoncé que Massimo Radaelli, PDG de Napo Therapeutics et président de Jaguar International, a été nommé 'Meilleur Innovateur Pharmaceutique de l'Année - Europe' par la publication The European.

Ladenburg Thalmann veranstaltet am 18. Dezember 2024 ein Webinar zum Scientific Showcase, das sich auf die klinische Entwicklung von Jaguar Health (NASDAQ:JAGX) des pflanzenbasierten Antidiarrhoikums Crofelemere konzentriert. Die Veranstaltung wird fünf laufende klinische Bemühungen zu seltenen Krankheiten hervorheben: drei von Forschern initiierte Proof-of-Concept-Studien und zwei Phase-2-Studien, die auf Mikroviillius-Insuffizienzkrankheit (MVID) und kurzes Darm-Syndrom mit intestinaler Insuffizienz (SBS-IF) in den USA, der EU und der Region Naher Osten/Nordafrika abzielen. Erste Proof-of-Concept-Ergebnisse werden für das zweite Quartal 2025 erwartet. Das Unternehmen gab auch bekannt, dass Massimo Radaelli, CEO von Napo Therapeutics und Präsident von Jaguar International, von der Publikation The European zum 'Besten Pharma Innovator des Jahres - Europa' ernannt wurde.

Positive
  • Five ongoing clinical trials for rare disease indications
  • Proof-of-concept results expected in Q2 2025
  • Recognition from European publication for pharmaceutical innovation
Negative
  • None.

Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025

Virtual event 11:00 AM to 12:00 PM Eastern

Registration open now for financial and business community; Click here to register

Massimo Radaelli, PhD, CEO of the rare disease-focused Jaguar family company Napo Therapeutics and President of Jaguar International, named ‘Best CEO BioPharmaceuticals of the Year'

SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Ladenburg Thalmann is hosting a Scientific Showcase webinar on Wednesday, December 18, 2024 from 11:00 a.m. to 12:00 p.m. EST about clinical development efforts for crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the ultrarare congenital diarrheal disorder MVID and the rare disease SBS-IF. To register for this virtual event, which is open to the financial and business community, click here.

Jaguar founder and CEO Lisa Conte and Pravin Chaturvedi, PhD, Jaguar's Chief Scientific Officer and Chair of the company's Scientific Advisory Board, will participate in the virtual event.

Participation Instructions for Scientific Showcase

Event is exclusively for investors, financial analysts, business media, and business development executives.

When: Wednesday, December 18, 2024 from 11:00 a.m. to 12:00 p.m. EST

Registration Link: Click Here

"We're thrilled to announce that Massimo Radaelli, PhD, CEO of the rare disease-focused Jaguar family company Napo Therapeutics and President of Jaguar International, has been named "Best Pharmaceuticals Innovator of the Year - Europe" by The European, a quarterly business publication published by CP Media Global Ltd in London," said Lisa Conte, Jaguar's president and CEO. "This award is well deserved, reflecting Massimo's lifetime of dedication and pioneering vision in the industry. As announced last month, The European also named Napo Therapeutics "Best Pharmaceuticals Innovator of the Year - Europe" for 2024 - additional welcome recognition of ongoing efforts by Massimo and Napo Therapeutics to expand access to crofelemer in Europe for orphan and/or rare diseases, initially for MVID and SBS-IF."

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements related to the expectation that Ladenburg Thalmann will host a Scientific Showcase on December 18, 2024 about Jaguar Health's rare disease clinical development efforts, and Jaguar's expectation that availability of IIT proof-of-concept results of crofelemer in MVID and/or SBS-IF may potentially occur in Q2 2025. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on accesswire.com

FAQ

What are the current clinical trials for Jaguar Health's crofelemer (JAGX)?

Crofelemer is currently involved in five clinical efforts: three proof-of-concept investigator-initiated trials and two Phase 2 studies, targeting MVID and SBS-IF across US, EU, and Middle East/North Africa regions.

When will the results of JAGX's crofelemer proof-of-concept trials be available?

The proof-of-concept trial results for crofelemer are potentially expected in Q2 2025.

What rare diseases is JAGX's crofelemer targeting in clinical trials?

Crofelemer is targeting two rare diseases: microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).

What is the purpose of JAGX's December 18, 2024 Scientific Showcase?

The Scientific Showcase will present clinical development efforts for crofelemer in treating rare diseases MVID and SBS-IF to the financial and business community.

Jaguar Health, Inc.

NASDAQ:JAGX

JAGX Rankings

JAGX Latest News

JAGX Stock Data

10.70M
10.69M
12.02%
1.96%
3.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO